

November 24, 2023

VIA EDGAR

Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Doris Stacey Gama

**RE: SAB Biotherapeutics, Inc.
Registration Statement on Form S-3
File No. 333-275319
Filed November 3, 2023; amended November 20, 2023**

In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, SAB Biotherapeutics, Inc. (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Tuesday, November 28, 2023 at 5:00 p.m., Eastern Time, or as soon as thereafter practicable.

Please call Ilan Katz of Dentons US LLP at (212) 632-5556 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,

SAB Biotherapeutics, Inc.

/s/ Eddie J. Sullivan

Eddie J. Sullivan
Chief Executive Officer

cc: Ilan Katz, Dentons US LLP

US_ACTIVE\123165070V-1
